A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma

Trial Profile

A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2019, as reported by ClinicalTrials.gov.
    • 10 Aug 2015 Planned primary completion date changed from 1 Aug 2014 to 1 May 2015, as reported by ClinicalTrials.gov.
    • 16 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top